Unlearn.AI Announces Series A Extension with New Investment from Epic Ventures, Alumni Ventures Group, and Global Pharma Company Eisai

SAN FRANCISCO--(BUSINESS WIRE)--Unlearn®, developer of the first machine-learning platform that creates Digital Twins used to populate Intelligent Control Arms in clinical studies, today announced that Eisai, a leading global research and development-based pharmaceutical company, has joined the company’s world-class syndicate of investors as part of its Series A extension along with Epic Ventures and Alumni Ventures Group. In April 2020, Unlearn announced Series A financing led by 8VC with participation from DCVC, DCVC Bio and Mubadala Capital Ventures. The extension brings the Series A total to $15 million.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Webinars

Applying Machine Learning to Increase Clinical Trial Efficiency: A Regulatory Journey

Press

Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials

Press

Unlearn Signs Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany to Accelerate Immunology Trials using Twintelligent RCTs™

Collaborators will leverage AI-generated Digital Twins to enable smaller, more efficient pivotal clinical trials.
Led by Insight Partners, financing builds on the company’s momentum in working with leading biopharmaceutical companies to improve clinical trial efficiency.
Learn about the evolution of ideas that led to our TwinRCT™ solution for smaller, more efficient clinical trials and recent EMA draft qualification opinion.